FDA Approves Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease

The U.S. FDA has approved Enspryng (satralizumab) for adults with thyroid eye disease (TED). This interleukin-6 receptor inhibitor is the first subcutaneous therapy for TED that patients or caregivers can administer at home after training. This decision, following a priority review, expands treatment options and marks Enspryng's second indication.